Core Concepts
Man with terminal heart disease, Lawrence Faucette, who received a genetically modified pig heart transplant, passed away, highlighting the challenges and risks of xenotransplantation.
Abstract
Lawrence Faucette, a 58-year-old man with terminal heart disease, received a genetically modified pig heart transplant at the University of Maryland Medical Center (UMMC) after being turned down for a standard allograft transplantation. Despite initial progress, Faucette's heart showed signs of rejection, leading to his passing. The medical team aims to learn from this experience to improve future xenotransplant procedures.
Lawrence Faucette received a pig heart transplant on September 20, 2023, after being admitted to UMMC in end-stage heart failure.
The US FDA granted emergency authorization for the surgery through its single-patient investigational new drug compassionate use pathway.
Faucette expressed hope and gratitude for the opportunity the pig heart transplant provided him.
Despite initial progress and participation in physical therapy, Faucette's heart showed signs of rejection before his passing.
The medical team, led by Dr. Bartley P. Griffith, aims to learn from Faucette's case to improve future xenotransplant procedures.
Dr. Muhammad M. Mohiuddin highlighted Faucette's contribution to advancing the field of xenotransplantation and emphasized the importance of learning from each case.
UMMC performed the first genetically modified pig heart transplant in January 2022, with the recipient surviving for 60 days.
Stats
Lawrence Faucette received the pig heart transplant on September 20, 2023.
The first genetically modified pig heart transplant was performed in January 2022.
Quotes
"My only real hope left is to go with the pig heart, the xenotransplant." - Lawrence Faucette
"Mr Faucette's last wish was for us to make the most of what we have learned from our experience, so others may be guaranteed a chance for a new heart when a human organ is unavailable." - Dr. Bartley P. Griffith